File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Recent advances in the treatment of lymphomas

TitleRecent advances in the treatment of lymphomas
Authors
KeywordsAntibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols
Lymphoma, Extranodal Nk-T-Cell
Lymphoma, Follicular
Prednisone
Vincristine
Issue Date2010
PublisherScientific Communications International Ltd. The Journal's web site is located at http://www.hkcr.org/
Citation
Journal Of The Hong Kong College Of Radiologists, 2010, v. 13 n. 3 SUPPL., p. 22-24 How to Cite?
AbstractMalignant lymphoma is a common neoplasm and some are potentially curable if appropriate therapy is given. The use of the monoclonal anti-CD20 antibody rituximab in the management of follicular lymphoma has improved the outcome of patients. Rituximab and chemotherapy combination is now standard in the initial treatment of advanced-stage follicular lymphoma. Furthermore, rituximab maintenance therapy has also been shown to prolong progression-free survival in first clinical remission as well as in relapse following salvage therapy. In addition to rituximab, the use of purine analogue fludarabine in follicular lymphoma has also been shown to enhance the response rate. On the other hand, chemotherapy designed for the treatment of B-cell lymphoma is generally ineffective for NK/T-cell lymphoma, a highly malignant lymphoma that is prevalent in Asian countries. Recently, preliminary results from international study and our local centre have shown that the SMILE regimen (comprising dexamethasone, methotrexate, ifosphamide, L-asparaginase and etoposide) is very effective and would potentially improve the survival of patients with NK/T-cell lymphoma. © 2010 Hong Kong College of Radiologists.
Persistent Identifierhttp://hdl.handle.net/10722/163363
ISSN
References

 

DC FieldValueLanguage
dc.contributor.authorTse, Een_US
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2012-09-05T05:30:34Z-
dc.date.available2012-09-05T05:30:34Z-
dc.date.issued2010en_US
dc.identifier.citationJournal Of The Hong Kong College Of Radiologists, 2010, v. 13 n. 3 SUPPL., p. 22-24en_US
dc.identifier.issn1029-5097en_US
dc.identifier.urihttp://hdl.handle.net/10722/163363-
dc.description.abstractMalignant lymphoma is a common neoplasm and some are potentially curable if appropriate therapy is given. The use of the monoclonal anti-CD20 antibody rituximab in the management of follicular lymphoma has improved the outcome of patients. Rituximab and chemotherapy combination is now standard in the initial treatment of advanced-stage follicular lymphoma. Furthermore, rituximab maintenance therapy has also been shown to prolong progression-free survival in first clinical remission as well as in relapse following salvage therapy. In addition to rituximab, the use of purine analogue fludarabine in follicular lymphoma has also been shown to enhance the response rate. On the other hand, chemotherapy designed for the treatment of B-cell lymphoma is generally ineffective for NK/T-cell lymphoma, a highly malignant lymphoma that is prevalent in Asian countries. Recently, preliminary results from international study and our local centre have shown that the SMILE regimen (comprising dexamethasone, methotrexate, ifosphamide, L-asparaginase and etoposide) is very effective and would potentially improve the survival of patients with NK/T-cell lymphoma. © 2010 Hong Kong College of Radiologists.en_US
dc.languageengen_US
dc.publisherScientific Communications International Ltd. The Journal's web site is located at http://www.hkcr.org/en_US
dc.relation.ispartofJournal of the Hong Kong College of Radiologistsen_US
dc.subjectAntibodies, Monoclonalen_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectLymphoma, Extranodal Nk-T-Cellen_US
dc.subjectLymphoma, Follicularen_US
dc.subjectPrednisoneen_US
dc.subjectVincristineen_US
dc.titleRecent advances in the treatment of lymphomasen_US
dc.typeArticleen_US
dc.identifier.emailTse, E:ewctse@hku.hken_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.authorityTse, E=rp00471en_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.scopuseid_2-s2.0-79952066483en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79952066483&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume13en_US
dc.identifier.issue3 SUPPL.en_US
dc.identifier.spage22en_US
dc.identifier.epage24en_US
dc.publisher.placeHong Kongen_US
dc.identifier.scopusauthoridTse, E=7005019454en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats